Services
GST Registration Online
Elpro International Acquires Stake in Blue Jet Healthcare for INR 7.54 Crores
Team Finance Saathi
17/Dec/2024
What's Covered Under the Article:
- Elpro International acquires 1,38,366 equity shares of Blue Jet Healthcare for investment purposes.
- Blue Jet Healthcare, a pharmaceutical company, has a turnover of INR 7,404.58 million in FY 2023-24.
- The acquisition enhances Elpro International's portfolio in the pharmaceutical sector.
Elpro International Limited, a leading entity in diversified investments, has announced the acquisition of 1,38,366 equity shares of Blue Jet Healthcare Limited for a total cash consideration of INR 7.54 crores. This strategic acquisition marks Elpro’s entry into the pharmaceutical sector, reinforcing its interest in companies with robust operations and global presence. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency for investors and stakeholders.
About Blue Jet Healthcare Limited
Blue Jet Healthcare Limited is a globally recognized, science-driven pharmaceutical company specializing in the manufacturing of advanced pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company, incorporated on December 7, 1968, has built a strong reputation as a strategic partner for global pharmaceutical leaders. Its operations span more than 50 countries worldwide, including the USA, Norway, Denmark, Switzerland, France, Spain, and Thailand.
Financial Performance
Blue Jet Healthcare has demonstrated consistent performance over the last three financial years:
- FY 2023-24: Total turnover of INR 7,404.58 million (Revenue: INR 7,115.98 million; Other income: INR 288.60 million).
- FY 2022-23: Total turnover of INR 7,449.38 million.
- FY 2021-22: Total turnover of INR 7,028.81 million.
The company’s robust financials reflect its stability and strong market position in the pharmaceutical sector, making it an attractive investment for Elpro International.
Key Details of the Acquisition
- Nature of Acquisition: Fresh acquisition of 1,38,366 equity shares.
- Total Consideration: INR 7.54 crores, financed through cash.
- Previous Shareholding: Nil (This marks Elpro's first investment in Blue Jet Healthcare).
- Purpose: The acquisition is for investment purposes, aligning with Elpro’s strategy to diversify its portfolio across emerging industries like pharmaceuticals.
This move does not fall under related party transactions, as neither the promoter group nor group companies have any vested interest in Blue Jet Healthcare. The transaction was executed at arm’s length, ensuring fairness and transparency.
Strategic Importance of the Acquisition
The acquisition of Blue Jet Healthcare shares is a significant step for Elpro International as it ventures into the rapidly growing pharmaceutical industry. Blue Jet Healthcare is recognized for its focus on:
- High-quality manufacturing of pharmaceutical intermediates and APIs.
- Strong global partnerships and collaborations with pharmaceutical companies.
- Presence in over 50 international markets, reflecting its credibility and operational efficiency.
The pharmaceutical industry in India has shown consistent growth, driven by rising healthcare needs, increased demand for APIs, and India’s position as a global manufacturing hub. Blue Jet Healthcare’s ability to deliver customized solutions to global pharmaceutical players further strengthens its competitive edge in the market.
Elpro International’s Strategic Focus
Elpro International has a strong track record of identifying investment opportunities across diverse sectors. While its core operations span electrical and real estate sectors, this acquisition highlights its intent to tap into emerging industries like pharmaceuticals that promise long-term growth and stability.
The Pharmaceutical Sector’s Potential
The Indian pharmaceutical industry is a key player in the global market, contributing significantly to the supply of generic drugs and APIs. With an increasing focus on research and development and high-quality manufacturing, companies like Blue Jet Healthcare are well-positioned to capitalize on the rising demand for pharmaceutical products.
Moreover, the global demand for advanced pharmaceutical intermediates and APIs is expected to grow significantly, driven by:
- Increased investment in drug development and manufacturing.
- Rising healthcare expenditure worldwide.
- Expanding markets in Europe, the USA, and emerging economies.
Blue Jet Healthcare’s extensive global reach and innovative product offerings align well with these growth trends, making it a valuable addition to Elpro International's investment portfolio.
Conclusion
The acquisition of equity shares in Blue Jet Healthcare for INR 7.54 crores is a strategic move by Elpro International, reflecting its confidence in the pharmaceutical sector’s growth potential. This investment aligns with Elpro’s vision of diversifying its portfolio while investing in high-performing companies with robust operations and global presence.
As Elpro International continues to explore new opportunities, its latest acquisition is expected to deliver significant value to shareholders, strengthening its long-term growth strategy.